Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing–Remitting Multiple Sclerosis-Reference-Cited by-同舟云学术

Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing–Remitting Multiple Sclerosis

Published:2016-02-08 Issue:2 Volume:13 Page:428-438
ISSN:1933-7213
Container-title:Neurotherapeutics
language:en
Short-container-title:Neurotherapeutics

Author:

Orefice Nicola S.,Alhouayek Mireille,Carotenuto Antonio,Montella Silvana,Barbato Franscesco,Comelli Albert,Calignano Antonio,Muccioli Giulio G.,Orefice Giuseppe

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Clinical Neurology,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s13311-016-0420-z.pdf

Reference73 articles.

1. Cadas H, Schinelli S, Piomelli D. Membrane localization of N-acylphosphatidylethonolamine in central neurons: studies with exogenous phospholipases. J. Lipid Mediat Cell Signal 1996;14:63–70.

2. Alhouayek M, Muccioli GG. Harnessing the anti-inflammatory potential of palmitoylethanolamide Drug Discov Today 2014;19:1632-1639.

3. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998;394:277-281.

4. Calignano A, La Rana G, Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitoylethanolamide. Eur J Pharmacol 2001;419:191-198.

5. Lo Verme J, Russo R, La Rana G, et al. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 2006;319:1051-1061.

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ultramicronized N-palmitoylethanolamine associated with analgesics: Effects against persistent pain;Pharmacology & Therapeutics;2024-06

2. The Supplementation Therapy in Autism and Response to Treatment (START) Study: An Open-Label Feasibility Trial of Ultramicronized Palmitoylethanolamide Potential to Alleviate Psychic Distress among Autistic Adults;Clinical and Translational Neuroscience;2024-05-29

3. Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis;Nutrients;2024-05-28

4. Palmitoylethanolamide shows limited efficacy in controlling cerebral cryptococcosis in vivo;Antimicrobial Agents and Chemotherapy;2023-10-18

5. Palmitoylethanolamide shows limited efficacy in controlling cerebral cryptococcosisin vivo;2023-04-12